Changes

**1-2% of all non-Hodgkin lymphomas

**1-2% of all non-Hodgkin lymphomas

==Clinical Features<small><ref>{{Cite journal|last=A|first=Dogan|last2=Ad|first2=Attygalle|last3=C|first3=Kyriakou|date=2003|title=Angioimmunoblastic T-cell lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/12780782/|language=en|pmid=12780782}}</ref><ref>{{Cite journal|last=F|first=Lachenal|last2=F|first2=Berger|last3=H|first3=Ghesquières|last4=P|first4=Biron|last5=A|first5=Hot|last6=E|first6=Callet-Bauchu|last7=C|first7=Chassagne|last8=B|first8=Coiffier|last9=I|first9=Durieu|date=2007|title=Angioimmunoblastic T-cell lymphoma: clinical and laboratory features at diagnosis in 77 patients|url=https://pubmed.ncbi.nlm.nih.gov/17873758/|language=en|pmid=17873758}}</ref><ref>{{Cite journal|last=N|first=Mourad|last2=N|first2=Mounier|last3=J|first3=Brière|last4=E|first4=Raffoux|last5=A|first5=Delmer|last6=A|first6=Feller|last7=Cj|first7=Meijer|last8=Jf|first8=Emile|last9=R|first9=Bouabdallah|date=2008|title=Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials|url=https://pubmed.ncbi.nlm.nih.gov/18292286/|language=en|doi=10.1182/blood-2007-08-105759|pmc=PMC2343588|pmid=18292286}}</ref><ref>{{Cite journal|last=W|first=Siegert|last2=C|first2=Nerl|last3=A|first3=Agthe|last4=M|first4=Engelhard|last5=G|first5=Brittinger|last6=M|first6=Tiemann|last7=K|first7=Lennert|last8=D|first8=Huhn|date=1995|title=Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group|url=https://pubmed.ncbi.nlm.nih.gov/8664186/|language=en|pmid=8664186}}</ref></small>==

==Clinical Features<small><ref>{{Cite journal|last=F|first=Lachenal|last2=F|first2=Berger|last3=H|first3=Ghesquières|last4=P|first4=Biron|last5=A|first5=Hot|last6=E|first6=Callet-Bauchu|last7=C|first7=Chassagne|last8=B|first8=Coiffier|last9=I|first9=Durieu|date=2007|title=Angioimmunoblastic T-cell lymphoma: clinical and laboratory features at diagnosis in 77 patients|url=https://pubmed.ncbi.nlm.nih.gov/17873758/|language=en|pmid=17873758}}</ref><ref>{{Cite journal|last=N|first=Mourad|last2=N|first2=Mounier|last3=J|first3=Brière|last4=E|first4=Raffoux|last5=A|first5=Delmer|last6=A|first6=Feller|last7=Cj|first7=Meijer|last8=Jf|first8=Emile|last9=R|first9=Bouabdallah|date=2008|title=Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials|url=https://pubmed.ncbi.nlm.nih.gov/18292286/|language=en|doi=10.1182/blood-2007-08-105759|pmc=PMC2343588|pmid=18292286}}</ref><ref>{{Cite journal|last=W|first=Siegert|last2=C|first2=Nerl|last3=A|first3=Agthe|last4=M|first4=Engelhard|last5=G|first5=Brittinger|last6=M|first6=Tiemann|last7=K|first7=Lennert|last8=D|first8=Huhn|date=1995|title=Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group|url=https://pubmed.ncbi.nlm.nih.gov/8664186/|language=en|pmid=8664186}}</ref></small>==

'''Sign and Symptoms'''

'''Sign and Symptoms'''